Immunotherapy, Targeted Therapy, and Their Cross Talks in Hepatocellular Carcinoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jan 4

PMID 38173713

Authors

Jun Liu

Kevin Park

Ziyang Shen

Hannah Lee

Purnima Geetha

Mohammadreza Pakyari

Li Chai

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a challenging malignancy with limited treatment options beyond surgery and chemotherapy. Recent advancements in targeted therapies and immunotherapy, including PD-1 and PD-L1 monoclonal antibodies, have shown promise, but their efficacy has not met expectations. Biomarker testing and personalized medicine based on genetic mutations and other biomarkers represent the future direction for HCC treatment. To address these challenges and opportunities, this comprehensive review discusses the progress made in targeted therapies and immunotherapies for HCC, focusing on dissecting the rationales, opportunities, and challenges for combining these modalities. The liver's unique physiology and the presence of fibrosis in many HCC patients pose additional challenges to drug delivery and efficacy. Ongoing efforts in biomarker development and combination therapy design, especially in the context of immunotherapies, hold promise for improving outcomes in advanced HCC. Through exploring the advancements in biomarkers and targeted therapies, this review provides insights into the challenges and opportunities in the field and proposes strategies for rational combination therapy design.

Citing Articles

Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation.

Pan X, Zhou Y, Li Z, Guo P, Zeng J, Dong X Commun Med (Lond). 2025; 5(1):65.

PMID: 40050645 PMC: 11885828. DOI: 10.1038/s43856-025-00784-z.

Tailoring traditional Chinese medicine in cancer therapy.

Li S, Chen X, Shi H, Yi M, Xiong B, Li T Mol Cancer. 2025; 24(1):27.

PMID: 39838407 PMC: 11749133. DOI: 10.1186/s12943-024-02213-6.

Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma.

Yue Q, Li X, Wan X, Lin X, Li Y, Zhang M Cancer Med. 2025; 14(1):e70570.

PMID: 39778021 PMC: 11705445. DOI: 10.1002/cam4.70570.

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma.

Zou H, Lai Y, Chen X, Ung C, Hu H Therap Adv Gastroenterol. 2025; 18:17562848241310314.

PMID: 39758963 PMC: 11694292. DOI: 10.1177/17562848241310314.

PPIH Expression Correlates with Tumor Aggressiveness and Immune Dysregulation in Hepatocellular Carcinoma.

Bei J, Sun Z, Fu R, Huang X, Huang J, Luo Y J Hepatocell Carcinoma. 2024; 11:2453-2470.

PMID: 39679070 PMC: 11646373. DOI: 10.2147/JHC.S492420.

References

Nicole L, Sanavia T, Veronese N, Cappellesso R, Luchini C, Dabrilli P . Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis. Oncotarget. 2017; 8(14):22968-22979. PMC: 5410278. DOI: 10.18632/oncotarget.14952. View

Tanaka Y, Aishima S, Kohashi K, Okumura Y, Wang H, Hida T . Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma. Histopathology. 2015; 68(5):693-701. DOI: 10.1111/his.12806. View

Hastie N . Wilms' tumour 1 (WT1) in development, homeostasis and disease. Development. 2017; 144(16):2862-2872. DOI: 10.1242/dev.153163. View

Ng C, Di Costanzo G, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G . Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol. 2018; 29(5):1286-1291. DOI: 10.1093/annonc/mdy083. View

Waidmann O . Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2018; 18(8):905-910. DOI: 10.1080/14712598.2018.1499722. View

Wilson G, Tennant D, McKeating J . Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014; 61(6):1397-406. DOI: 10.1016/j.jhep.2014.08.025. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Bohm J, Sustmann C, Wilhelm C, Kohlhase J . SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway. Biochem Biophys Res Commun. 2006; 348(3):898-907. DOI: 10.1016/j.bbrc.2006.07.124. View

Tan J, Li F, Yeo J, Yong K, Bassal M, Ng G . New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. Gastroenterology. 2019; 157(6):1615-1629.e17. PMC: 7309153. DOI: 10.1053/j.gastro.2019.08.022. View

10.

Sun B, Xu L, Bi W, Ou W . SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance. Int J Mol Sci. 2022; 23(4). PMC: 8876671. DOI: 10.3390/ijms23042053. View

11.

Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, von Wasielewski R . Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer. 2011; 47(7):1080-5. DOI: 10.1016/j.ejca.2010.11.015. View

12.

Hanif H, Ali M, Susheela A, Khan I, Luna-Cuadros M, Khan M . Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022; 28(2):216-229. PMC: 8776528. DOI: 10.3748/wjg.v28.i2.216. View

13.

Hussain S, Schwank J, Staib F, Wang X, Harris C . TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007; 26(15):2166-76. DOI: 10.1038/sj.onc.1210279. View

14.

Doe M, Ascano J, Kaur M, Cole M . Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res. 2011; 72(4):949-57. PMC: 3288382. DOI: 10.1158/0008-5472.CAN-11-2371. View

15.

Ghamande S, Lin C, Cho D, Shapiro G, Kwak E, Silverman M . A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2013; 32(3):445-51. DOI: 10.1007/s10637-013-0044-7. View

16.

Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G . Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol. 2021; 10:601240. PMC: 7874239. DOI: 10.3389/fonc.2020.601240. View

17.

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

18.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

19.

Mouhoubi N, Bamba-Funck J, Sutton A, Blaise L, Seror O, Ganne-Carrie N . Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023; 9:1369-1383. PMC: 9805748. DOI: 10.2147/JHC.S382226. View

20.

Zhang J, Zhang M, Ma H, Song X, He L, Ye X . Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore). 2018; 97(24):e11130. PMC: 6024095. DOI: 10.1097/MD.0000000000011130. View